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Introduction. Different definitions of periprocedural myocardial infarction (MI) after Percutaneous 
Coronary Intervention (PCI) have been provided, but their impact on prognosis remains to be 
determined. 
Methods. Procedural data from consecutive patients undergoing PCI from 2009 to 2011 were 
revised to adjudicate diagnosis of periprocedural MI according to CK-MB increase (>3 x URL and 
>5 x URL), to troponin increase (>3 x 99
th 
percentile URL and >5 x 99
th 
percentile URL) and to 
recent 2012 Task and SCAI definitions. MACE (Major Adverse Cardiovascular Events) was the 
primary end point. 
Results. 712 patients were enrolled: after 771 days, 115 (16.7%) patients experienced MACE. 190 
patients were diagnosed a periprocedural MI defined as elevation of troponin >5x99
th 
percentile of 
URL. When adjudicating 2012 Task Force definition on these patients, 46 were excluded and 1.4% 
of them experienced a MACE and 0.3% died, while among 144 with periprocedural MI, 2.9% 
reported a MACE and 1.3% died. After appraisal of SCAI definition, 176 patients were excluded, 
3.8% of them with a MACE and 1.4% died, and for those with periprocedural MI, 0.5% 
experienced a MACE and 0.1% died. Similar low performance was appraised after reclassification 
of patients from more than 3 of upper limit of CK-MB and of troponin. At multivariate analysis, 
none of these definitions related to adverse events. 
Conclusion. Periprocedural MI represents a frequent complication for patients undergoing PCI. Al 
present definitions share a still not satisfactory discrimination between patients with and without 
adverse events at follow up, stressing the need for more accurate definitions. 
 











Cardiac biomarkers elevation may often occur after percutaneous coronary interventions (PCI) due 





. The term PCI-related myocardial infarction has been introduced to refer to this 
pathological finding but many different cut-offs and biomarkers (i.e. CK.MB and Troponins) have 
been used to define this entity, resulting in a complex and variegated picture.  Moreover, while 
originally associated with a worsened outcome
3 ,4
, many recent reports have failed to show a 
consistent prognostic value related to PCI-related myocardial infarction, especially when Troponins 




As a consequence, to date, no definite conclusions can be drawn about the clinical relevance of 
procedural-related increases in cardiac biomarkers
7
. In the attempt to address these issues, two 
consensus papers have been recently released to provide unanimous directives on this topic. First, 
the ESC, ACCF, AHA and WHF Task Force for the Third universal definition of myocardial 
infarction, arbitrarily restricted the diagnosis of myocardial infarction with PCI (the type 4a MI, 
from now on “2012 Task Force definition”) only to those patients with symptoms or instrumental 
signs of myocardial ischemia associated with the increase in Troponin
8
. More recently, the Society 
for Cardiovascular Angiography and Interventions (SCAI), formulated new definitions selecting 
biomarkers cutoffs clearly associated with a worsened prognosis after literature review (referred to 
as “SCAI definition” from now on)
9
.  However, since a clinical validation of these formulated 
criteria is lacking, we conducted this study with the aim to assess the prognostic value of new 










All consecutive patients undergoing PCI both elective both for Unstable Angina (UA) in our Center 
(defined as index hospitalization) between January 2009 and January 2011 (Division of Cardiology, 
University of Turin) were included and recorded in the electronic database of our Institution 
(Azienda Ospedaliera Città della Salute e della Scienza). Patients with myocardial infarction were 




Baseline and interventional features were analyzed through revisiting medical records about 
hospitalizations for PCIs registered on dedicated Medical Records Process Management
11
. All 
variables were defined according to definitions of Euro Heart PCI score
12 
or, if not reported there, to 
international guidelines. Patients were deemed to have valvular disease if at least of moderate 
entity. EuroHeartPCI score was retrospectively elaborated
13
. In patients presenting with unstable 
angina, pre-procedural increases of Troponin and CK-MB were ruled out performing at least 3 
measurements over an interval time of at least 12 hours from last symptoms appearance. Heparin 
was the anticoagulant of choise during PCI. Patients were treated according to current guidelines at 
discharge; double antiplatelet therapy (DAT) was administered for at least 1 month in the case of 




Periprocedural myocardial infarction was defined according to previously published criteria as: a 
CK-MB increase >3 x URL; a CK-MB increase >5 x URL
14








. Moreover, according to the 
2012 Task Force definition, as a Troponin increase >5 x 99
th 
percentile URL associated with at least 
one among prolonged chest pain (≥20 min), ischemic ST changes and/or Q waves, angiographic 
evidence of a flow limiting complication or imaging evidence of new loss of viable myocardium or 
 
 
new regional wall motion abnormality
8
; and, according to the SCAI definition, as a CK-MB 
increase ≥10 x URL, or ≥5 x URL with new pathologic Q-waves in ≥2 contiguous leads or new 
persistent LBBB, or a cTn increase ≥70 x URL, or ≥35 x URL with new pathologic Q-waves in ≥2 




Increases of myocardial biomarkers were due to happen 
within 48 hours after PCI.
 
 
MACE (that is death, myocardial infarction and repeated revascularization) after a mean follow up 
of at least 365 days were the primary end points, while its single components the secondary ones. 
Data about both short term and long term outcomes derived from AURA (Anagrafe Unitaria 
Regionale Assistiti)
17
, an institutional database recording all hospitalizations in Piedmont. Data 




Continuous variables are expressed as mean ± standard deviation and were compared with 
ANOVA. Categorical variables are presented as counts and percentage and were compared with the 
chi-squared test. Statistical significance was set at the two-tailed 0.05 level. According to number of 
events for variables appraised and for differences in follow up
18,19
, six different models of Cox 
proportional hazard analysis were performed for MACE at long-term follow-up, including each 
different PCI-related myocardial infarction, age, gender, ejection fraction, renal creatinine clearance 
and all variables with differences at univariate analysis (p <0.05). For each model accuracy was 
evaluated with Area under the Curve (AUC), calibration with Hosmer-lemeshow test, the 
proportion of variance in the dependent variable associated with the predictor (independent) 
variables with and loss of information through Akaike information criterion.  Computations were 






A total of 712 patients were included in the present study, 318 (44.7%) of whom with a diagnosis of 
unstable angina. Baseline characteristics are shown in Table 1. According to the different 
definitions, PCI-related myocardial infarction was found, respectively, in 48 (6.7%, CK-MB >3 x 
URL MI), 22 (3.1%, CK-MB >5 x URL MI), 254 (35.7%, Tn >3 x 99
th 
percentile MI), 190 (26.7%, 
Tn >5 x 99
th 
percentile MI), 144 (20.2%, 2012 Task Force definition) and 14 (2.0%, SCAI 
definition). General characteristics of these subgroups are shown in Table 1. DAT wasn’t 
administered to 12 patients, who were treated with a single antiplatelet drug; of them, 2 (20%) 
experienced MACE (both rePCI).  
Study end-points 
After a mean follow up of 771±332 days, overall 115 (16.7%) patients experienced MACE. In 
detail, 35 (5.1%) died (24 [70.6%] to a CV disease), 18 (2.6%) experienced myocardial infarction, 
83 (12.0%) underwent recurrent PCI and 3 (0.4%) CABG (Table 2). At univariate analysis, age, 
creatinine clearance, EF, diabetes, valvular disease, increased levels of Troponin before the 
procedure, LM disease, CTO and Euro Heart PCI score were significantly associated with MACE at 
follow up. Table 3 shows univariate predictors and respective p-values for MACE and its single 
components. PCI-related myocardial infarction didn’t relate to MACE or to its single components at 
follow-up. Six different multivariate models, one for each PCI-related myocardial infarction 
definition, were conducted by Cox multivariate analysis to identify what parameters independently 
predicted MACE at follow up (Table 4). Other than PCI-related myocardial infarction, all variables 
significantly related to MACE at univariate analysis (p value <0.05) were included (age, creatinine 
clearance, EF, diabetes, valvular disease, pre-procedural Troponin increased values, LM disease, 
CTO and Euro Heart PCI score). Valvular heart disease (OR 2.0 95% CI 1.1-3.6, p=0.02) and 
baseline elevated Troponin levels before angioplasty (OR 0.3 95% CI 0.1-0.8, p=0.020) emerged as 
 
 
the lone independent predictors of MACE at follow up. Among the different definitions of PCI-
related myocardial infarction, only the SCAI definition showed a trend towards predicting MACE 
(OR 2.8 95% CI 0.9-9.1, p=0.08). 
Comparison among definitions 
We compared the different subgroups as determined by each definition. As shown in figure 1, some 
definitions (those based on CK-MB and the SCAI definition) include a small number of patients 
(respectively, 48, 22, 14, experiencing respectively 8, 3, 4 MACE), with the consequence of 
excluding most of the patients experiencing MACE (respectively, 107, 112, 111). The SCAI 
definition, for example, is able to identify a subset of patients with almost 1 out of 3 chances of 
experiencing MACE, but at the expenses of excluding more than the 95% of the overall MACE. 
Conversely, the 2012 Task Force definition includes a greater number of patients (respectively 254, 
190, 144) without being able to identify those with an increased risk. The subgroup identified by the 
latter definition is formed by a higher number of patients with unfavorable events as compared by 
the SCAI definition, but the rate of MACE was lower in this sample than in the SCAI group and 
than in the overall population, resulting in a poor performance at multivariate analysis (OR 0.855 
95% CI 0.5–1.5, p 0.58). Compared to the definition of Tn > 5 x 99
th 
MI, the 2012 Task Force 
definition excludes a subgroup of patients experiencing a rate of MACE higher than those included. 
As seen in Table 5, for each model accuracy was very low for MACE, all with an acceptable 











The main finding of our study is that all different definitions of PCI related myocardial infarctions 
failed to accurately detect adverse events after PCI, with similar rates of MACE and of death for 
those with and without MI in a single-center, real-life cohort, of patients, after a follow up of more 
than 2 years.  Peri-procedural MI has been longtime considered equivalent to spontaneous MI, since 
the amount of biomarkers increase in the two events is often comparable. These two myocardial 





. Spontaneous MI represents the expression of the occlusion of a coronary artery, 
while PCI-related MI is an event related to the reopening of a diseased vessel. In two recent 
analysis, only spontaneous MI conferred an increased risk of death at long term follow up
20,21
. 
Different physiopathologies may exist even among PCI-related MI, as only unsuccessful procedures 
have been shown to relate to an adverse outcome as opposed to successful procedures, despite 
similar amounts of biomarkers increases
22
. Variability in rates of unsuccessful procedures in 
different cath labs may contribute to justify the inconsistent results on PCI-related myocardial 
infarction and it could be affected by the quality of care of the different centers performing PCI. 
Highly variable rates of periprocedural MI are described in literature, due to differences in 
definitions adopted, population characteristics and type and techniques pf PCI performed; thebrates 
found in our study are similar to those found in other, larger, series
23,24,25
.  
Any definition tested in our study proved unable to discriminate from the overall population those 
patients encountering a substantially increased amount of unfavorable events at follow up, even 
when using the newly introduced definitions from 2012 Task Force
8
 and from SCAI
9
. Each 
definition includes a too large or a too limited number of patients, with opposite consequences. In 
the first case, it is not possible to appraise patients at increased risk, and, in the second, too many 
patients experiencing considerable rates of events were excluded. Reclassification from one 
definition to another did not improve accuracy, with comparable rates of death and MACE in 
patients with and without different diagnosis of periprocedural MI. Only the SCAI definition 
 
 
showed a trend towards a relationship with MACE, but it included only a reduced number of, 
excluding in the process the majority of patients experiencing events. Similar results have emerged 
in recent years from several studies
5,6,21,23
 which described the post-procedural increases in cardiac 
biomarkers as epiphenomenons of a more severe underlying atherosclerotic burden, of an increased 
prevalence of three-vessel disease and/or left main artery disease and of more complex procedures, 
all factors per se explaining an increased risk of unfavorable events. Further indices of the inability 
of the 2012 Task Force definition to provide any additional prognostic value come from a recent 
report by Baker et al.
24
, as this definition didn’t related to death or MI after 1 year of follow up. 
Interestingly, this study showed a considerably lower rate of periprocedural MI defined according 
to the 2012 Task Force (2.1%) as compared to ours, even in the presence of very similar rates of 
periprocedural MI defined as Tn>3 x 99
th
 percentile MI (31.9%), and it demonstrated a better 
performance of both definitions at ROC analysis. The greater sample size, the exclusion of UA 
patients, the different end-points and the longer time span of enrolment in the study by Baker et al. 
could explain these differences. Events in the strudy by Baker et al. were assessed after a shorter 
follow up (1 years, > 2 years in our report), a noticeable difference that could explain the 
betterperformance at ROC analysis, since the clinical influence of periprocedural MI appear 
stronger in the early phases after PCI. Indeed, while long-term prognostic value of biomarkers 
elevations is increasingly doubted, some results recently converged showing a relationship between 
post-procedural MI and 30-days outcome, a finding underlining how PCI related myocardial 




Based on the comparison between our results and those by Baker et al, it has to be evaluated if 
adding clinical parameters to biomarkers levels dosing in the appraisal of periprocedural Mi may 
lead to greater variability in its adjudication. Concerning SCAI definition
9
, to our knowledgr to date 
no other studies attempted its validation in a clinical setting. 
10 
 
The low performance of all the definition casts doubt on the actual value and usefulness of cardiac 
biomarkers in the assessment of PCI-related myocardial damage
7
. Other parameters with a known 
strong prognostic value, particularly variations in left ventricular global function and regional wall 
motion, should be tested in this setting. Only a limited portion of these patients has been shown to 
develop lesions detectable by late-gadolinium enhancement at magnetic resonance imaging
24
, 
however with a still unknown impact on prognosis. Moreover, more data should be reported about 
patients presenting with multivessel coronary artery disease
25
, with particular coronary anatomy
26,27
 




Controversial results have emerged primarily from studies using Troponin (I or T) as the marker of 
choice, while with CK-MB has generally shown a greater agreement towards a prognostic value of 
periprocedural myocardial infarction, even if consistent results were shown only for markedly 
elevated levels
Errore. Il segnalibro non è definito.,Errore. Il segnalibro non è definito.,30
. The majority of the studies 
showing an unfavorable outcome with elevations in CK-MB included a high percentage of patients 
with ACS and, many post-procedural increases in CK-MB were actually pre-procedural
7,31
. More 
recent results from a population of patients with stable or unstable angina showed indeed no 
prognostic value for any CK-MB elevation (SPIRIT-IV trial, results provided in the SCAI 
consensus paper)
32
. In fact, either for CK-MB and Troponin, it has been clearly demonstrated the 
prognostic value of pre-procedural elevation in cardiac biomarkers, probably overcoming that of 
post -procedural elevations
5,33,34
, a result confirmed also by our present data. According to our data, 
the main criteria failed to provide substantial indications on the long-term outcome of the patients 
affected. However, given the limited number of events occurring in our population, definite 





Differences in physiopathology may explain the reports questioning if PCI-related MI actually 
significantly worsens the long-term outcome. Prasad and colleagues showed that myocardial 
necrosis after PCI didn’t predict long-term outcome
5
, as only pre-procedural elevations in 
myocardial biomarkers did. Similar conclusions were also drawn by Cavallini et al., even if their 
analysis excluded patients with elevations in CK-MB
6
. On the wake of these experiences, many 
authors started to question the clinical relevance of this finding and to doubt the need to monitor 
cardiac biomarkers after each procedure
7,31
. Moreover, the use of many different criteria to define 
PCI-related MI limited the interpretation of the results from different studies contributing to the 
confusion surrounding this topic. The publication of a new definition of the “MI type 4a” by 2012 
Task Force, with the aim to include in this definition only “clinically relevant events”
35
 tried to 
answer these questions, but being related, as stated by the authors, solely on arbitrarily chosen 
criteria. The consensus document released by the SCAI, in contrast, provided new criteria for the 
diagnosis of PCI related myocardial infarction that, pending a careful review of literature, would 





Due to the retrospective nature of our study, a confirmation on a prospectic cohort of these results is 




. Given limited 
statistical power of the study, conclusive inferences on the prognostic value of periprocedural MI 
should be avoided; the main finding of the present study is the overall poor performance of different 
definitions in selecting patients at increased risk. Moreover lack of data about pharmacological 
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FIGURE LEGENDS 
Figure 1. Definition of periprocedural myocardial infarction related to different defintions and risk 
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COPD (n.,%) 41 5.8 5* 10.4 2* 9.1 17* 6.7 15* 7.9 11* 7.6 1* 7.1 
<0.0
01 
TIMI flow (n, %) 




0 132 18.5 10 20.8 3 13.6 56 22 39 
20.
5 








5 2 2 1.1 2 1.4 0 
  
 
2 56 7.9 4 8.3 3 13.6 18 7.1 15 7.9 14 9.7 0 
  
 






78 54.2 10 
71.
4  






60* 41.7 7 50 
0.01
4 











LM disease (n, %) 
 
62 8.7 6 12.5 3 13.6 28 11 22 
11.
6 





Proximal LAD disease 
(n, %) 
 






















CTO (n, %) 
 











Rotational Atherectomy (n, 
%) 
14 2 1 2.1 1 4.5 9* 3.5 8* 4.2 6* 4.2 1 7.1 
0.03
7 
* marks the groups with statistically significant differences 
 
 
                                                                                                                                                                                        
MI, myocardial infarction; BMI, body mass index; LVEF, left ventricular ejection fraction; CABG, coronary artery by-pass 
graft; ICD, implantable cardioverter defibrillator, COPD, chronic obstructive pulmonary disease; LM, left main coronary; 

























                                                                                                                                                                                        





n = 712 
CK-MB > 3 x 
URL MI 
n = 48 
CK-MB > 5 x URL 
MI 
n = 22 
Tn > 3 x 99
th 
MI 
n = 254 
Tn > 5 x 99
th
 MI 
n = 190 
2012 Task 
Force definition 
n = 144 
SCAI 
definition 
n = 14 
 
Follow up (days) 771 ± 332 809 ± 269 792 ± 241 783 ± 332 759 ± 333 770 ± 334 749 
± 
288 
MACE (n, %) 115 16.7 8 16.7 3 13.6 47 18.8 31 16.7 21 14.9 4 28.6 
Death (n, %) 35 5.1 1 2.2 0  15 6.2 11 6.1 9 6.7 1 7.7 
Type of death (n, %)               
 
Non-CV  10 1.5 1 2.2 0  2 0.8 2 1.1 2 1.5 0 
 
 




6 2.5 4 2.2 4 3.0 1 7.7 
 




6 2.5 4 2.2 2 1.5 0 
 
AMI (n, %) 18 2.6 1 2.1 0  7 2.8 6 3.2 3 2.1 0  
rePCI (n,  %) 83 12.0 7 15.6 3 14.3 31 12.8 23 12.8 16 11.9 3 23.1 
CABG(n, %) 3 0.4 0  0  1 1.5 0  0  0  
 
MI, myocardial infarction; Non-CV, non cardiovascular death; CV AMI, cardiovascular death due to myocardial infarction; 
CV HF, cardiovascular death due to heart failure; AMI, acute myocardial infarction; rePCI, repeated percutaneous 













                                                                                                                                                                                        
Table 3. Univariate predictors of MACE and its single components  
MACE p Death p AMI p rePCI p 






0.001   Diabetes 0.002 





Diabetes 0.01 COPD < 0.001 
  
LM disease 0.016 
Valvular 
disease 











Euro Heart PCI 
score 
0.028 
LM disease 0.012 C type lesion 0.017 
    
CTO 0.012 
Euro Heart PCI 
score 
< 0.001 
    
Euro Heart PCI 
score 
0.004   
    
    
    
 
AMI, acute myocardial infarction; rePCI, repeated percutaneous coronary intervention; LVEF, left ventricular ejection fraction; LM, left 













                                                                                                                                                                                        
Table 4. Cox proportional hazards analysis testing independent predictors of MACE. 
Six different models were run, each for every different PCI-related myocardial 
infarction.  
 
 OR 95% CI p 
Age 1.022 0.992 – 1.053 0.148 
Creatinine clearance 1.002 0.992 – 1.011 0.746 
LVEF 0.990 0.969 – 1.011 0.354 
Diabetes 1.164 0.734 – 1.847 0.519 
Valvular disease 1.987 1.103 – 3.580 0.022 
Baseline elevated Troponin levels 0.301 0.110 – 0.829 0.020 
LM disease 1.240 0.651 – 2.362 0.512 
CTO 1.308 0.838 – 2.040 0.237 
Euro Heart PCI score 1.014 0.961 – 1.071 0.607 
CK-MB > 3 x URL MI 0.915 0.413 – 2.025 0.827 
CK-MB > 5 x URL MI 0.831 0.201 – 3.444 0.799 
Tn > 3 x 99
th 
MI 0.897 0.570 – 1.411 0.638 
Tn > 5 x 99
th 
MI 0.961 0.592 – 1.563 0.874 
2012 Task Force definition 0.855 0.493 – 1.484 0.578 
SCAI definition 2.830 0.876 – 9.144 0.082 
 














                                                                                                                                                                                        
Table 5. Area Under the Curve (AUC) for different definitions for MACE. 
 
  









CK-MB > 3 x URL MI 0.50 0.44 0.55 0.79 0.11 511 
CK-MB > 5 x URL MI 0.49 0.43 0.55 0.78 0.11 512 
Tn > 3 x 99
th 
MI 0.53 0.46 0.58 0.70 0.10 500 
Tn > 5 x 99
th
 MI 0.51 0.44 0.56 0.11 0.12 509 
2012 Task Force definition 0.48 0.43 0.56 0.08 0.11 510 
SCAI definition 0.48 0.43 0.55 0.81 0.12 511 
 
